Abstract

BRCA1‐associated protein‐1 (BAP1) expression is commonly lost in several tumors including malignant pleural mesothelioma (MPM). Presence or absence of immunohistochemical BAP1 nuclear staining in tumor cells is currently used for differential diagnosis of MPM. In this study, a large cohort of 596 MPM tumors with available clinical data was analyzed to examine associations of BAP1 staining pattern with clinical and molecular features that may reflect the impact of BAP1 mutation on MPM biology. Cases were classified according to the BAP1 staining pattern of tumor cells. Exome and RNA‐sequencing data were available for subsets of cases. Levels of mRNA encoding claudin 15 (CLDN15) and vimentin (VIM) were determined using RT‐qPCR on 483 cases to estimate the relative proportions of epithelial‐like and mesenchymal‐like components in each tumor. Four BAP1 staining patterns were observed: single‐pattern nuclear staining (36%), single‐pattern cytoplasmic staining (25%), single‐pattern absent staining (12%), and combinations of these staining patterns (27%). This study confirmed prior reports that nuclear BAP1 is more frequently associated with wild‐type BAP1 and sarcomatoid histology. However, no associations between BAP1 staining pattern(s) and mutations in specific protein domains and/or mutation type were observed. BAP1 staining patterns were significantly associated (p < 0.001) with BAP1 gene expression, MPM histologic subtypes, molecular clusters, and markers of epithelial‐to‐mesenchymal transition. Frequent observation of combinations of BAP1 staining patterns in MPM tumors indicated intra‐tumoral heterogeneity of BAP1 status. Cytoplasmic BAP1 staining was identified as a putative indicator of favorable prognosis in non‐epithelioid MPM. In conclusion, novel significant associations among different BAP1 staining patterns and subgroups of MPM tumors were observed, suggesting that the role of BAP1 in tumor progression may be more complex than its presumed tumor suppressor function. Cytoplasmic staining was identified as a putative indicator of favorable prognosis in non‐epithelioid MPM, potentially addressing a critical need in clinical decision‐making in this disease. © 2020 The Authors. The Journal of Pathology published by John Wiley & Sons, Ltd. on behalf of The Pathological Society of Great Britain and Ireland.

Highlights

  • Malignant pleural mesothelioma (MPM) is a rare aggressive tumor arising from the pleura and associated with asbestos exposure affecting 3200 patients annually in the US [1]

  • BRCA1-associated protein-1 (BAP1) protein consists of 729 amino acids and contains several domains including binding regions for protein interaction partners, and nuclear localization signal (NLS) targeting motifs required for nuclear localization [6]

  • Loss of BAP1 nuclear staining is considered a reliable indicator of malignancy, for epithelioid histology [21,24]

Read more

Summary

Introduction

Malignant pleural mesothelioma (MPM) is a rare aggressive tumor arising from the pleura and associated with asbestos exposure affecting 3200 patients annually in the US [1]. Prognosis is poor for all MPM patients, but those with non-epithelioid subtypes have a aggressive natural history and do not respond to currently available treatments [1]. BRCA1-associated protein-1 (BAP1), located at 3p21.1, a region frequently deleted in MPM, encodes a deubiquitinating enzyme that regulates key cellular pathways [2]. BAP1 is mutated in up to 60% of MPM samples, including germline mutations [3,4,5]. BAP1 protein consists of 729 amino acids and contains several domains including binding regions for protein interaction partners, and nuclear localization signal (NLS) targeting motifs required for nuclear localization [6]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call